Fiduciary Alliance LLC Grows Position in UnitedHealth Group Incorporated $UNH

Key Points

• Fiduciary Alliance LLC has increased its stake in UnitedHealth Group by 39.5%, owning 14,192 shares valued at approximately $4.43 million as of the latest SEC filing.
• UnitedHealth's stock opened at $348.05 and has a current market cap of $315.22 billion with a P/E ratio of 15.08.
• The company recently missed earnings estimates with $4.08 EPS reported, below the consensus of $4.45, despite a revenue increase of 12.9% year-over-year.

Fiduciary Alliance LLC lifted its stake in shares of UnitedHealth Group Incorporated (NYSE:UNH - Free Report) by 39.5% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 14,192 shares of the healthcare conglomerate's stock after acquiring an additional 4,020 shares during the period. Fiduciary Alliance LLC's holdings in UnitedHealth Group were worth $4,428,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the company. Bayforest Capital Ltd boosted its holdings in shares of UnitedHealth Group by 685.7% during the first quarter. Bayforest Capital Ltd now owns 55 shares of the healthcare conglomerate's stock worth $29,000 after purchasing an additional 48 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd boosted its stake in UnitedHealth Group by 416.7% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 62 shares of the healthcare conglomerate's stock worth $32,000 after buying an additional 50 shares during the last quarter. IAG Wealth Partners LLC purchased a new position in shares of UnitedHealth Group during the 1st quarter worth about $42,000. Copia Wealth Management purchased a new stake in UnitedHealth Group in the fourth quarter valued at approximately $42,000. Finally, O Brien Wealth Partners LLC raised its stake in UnitedHealth Group by 74.0% during the first quarter. O Brien Wealth Partners LLC now owns 87 shares of the healthcare conglomerate's stock worth $46,000 after purchasing an additional 37 shares during the period. 87.86% of the stock is owned by institutional investors and hedge funds.

UnitedHealth Group Trading Down 1.3%

UnitedHealth Group stock opened at $348.05 on Tuesday. The company has a market cap of $315.22 billion, a P/E ratio of 15.08, a PEG ratio of 2.30 and a beta of 0.44. UnitedHealth Group Incorporated has a 1 year low of $234.60 and a 1 year high of $630.73. The firm's 50-day moving average is $292.87 and its 200-day moving average is $367.43. The company has a debt-to-equity ratio of 0.73, a quick ratio of 0.85 and a current ratio of 0.85.

UnitedHealth Group (NYSE:UNH - Get Free Report) last issued its earnings results on Tuesday, July 29th. The healthcare conglomerate reported $4.08 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.45 by ($0.37). The business had revenue of $111.62 billion during the quarter, compared to the consensus estimate of $111.75 billion. UnitedHealth Group had a return on equity of 23.32% and a net margin of 5.04%.The business's revenue was up 12.9% on a year-over-year basis. During the same period in the prior year, the business earned $6.80 EPS. UnitedHealth Group has set its FY 2025 guidance at 16.000- EPS. On average, equities analysts expect that UnitedHealth Group Incorporated will post 29.54 earnings per share for the current year.

UnitedHealth Group Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 23rd. Stockholders of record on Monday, September 15th will be given a dividend of $2.21 per share. The ex-dividend date is Monday, September 15th. This represents a $8.84 annualized dividend and a dividend yield of 2.5%. UnitedHealth Group's dividend payout ratio is currently 38.30%.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on UNH. TD Cowen cut UnitedHealth Group from a "buy" rating to a "hold" rating and set a $308.00 target price on the stock. in a report on Monday, May 19th. Barclays increased their target price on shares of UnitedHealth Group from $337.00 to $352.00 and gave the stock an "overweight" rating in a research report on Thursday, September 4th. Wall Street Zen downgraded shares of UnitedHealth Group from a "buy" rating to a "hold" rating in a research note on Saturday, May 24th. Morgan Stanley lifted their target price on shares of UnitedHealth Group from $325.00 to $395.00 and gave the company an "overweight" rating in a report on Friday. Finally, HSBC reissued a "reduce" rating and issued a $270.00 price objective (down from $490.00) on shares of UnitedHealth Group in a research report on Wednesday, May 21st. Sixteen equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $358.95.

UnitedHealth Group Company Profile

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.